Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

The Sensex fell 721 points and the Nifty 50 dropped 225 points amid foreign fund withdrawals. Analysts predict upcoming ...

Bank of Baroda reported net profit at Rs 4,541 crore for Q1 FY26. This marks a 2 percent rise from the Rs 4,458 crore net ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

Cipla, India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs. The company's ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in ...

Cipla , India's No. 3 drugmaker by sales, reported a first-quarter profit that beat market expectations on Friday.